The ASF and FAST are excited to announce their partnership with the Institute for Gene Therapies (IGT)!
IGT brings together experts from all areas of healthcare to push for policies that help patients get available therapeutic treatments and encourage medical innovation.
Gene therapies are cutting-edge treatments that could offer lasting benefits with just a single dose. Yet, as scientific advancements outpace policy updates, it will become challenging for patients to access these groundbreaking therapies. By teaming up with IGT, its Corporate Advisory Council, dozens of other rare disease advocacy groups, and experts from science, medicine, and academia, ASF and FAST are working to create positive changes in healthcare policy. The ASF and FAST are committed to mobilizing and empowering more advocacy endeavors on a federal, state, and local level to make sure patients can access every therapeutic treatment option.